Cytotoxic chemotherapy may enhance the antitumor response of PD-1/PD-L1 antibodies by increasing antigen cross-presentation by dendritic cells after the destruction of tumor cells, inhibiting myeloid-derived suppressor cells and increasing the ratio of cytotoxic lymphocytes to regulatory T cells. This evidence concerns the gene CD274 and neoplasm.